Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________
 FORM 8-K
 ______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 7, 2017
 ______________________________
 
 
 
 
 
 
LIFEVANTAGE CORPORATION
(Exact name of registrant as specified in its charter)
______________________________
 
 
 
 
 
 
Colorado
 
001-35647
 
90-0224471
(State or other Jurisdiction of Incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)
 
 
9785 S. Monroe Street, Suite 300, Sandy, UT 84070
(Address of Principal Executive Offices and Zip Code)
 
 
 
 
 
Registrant’s telephone number, including area code: (801) 432-9000
_____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o





Item 2.02.    Results of Operations and Financial Condition.
On September 7, 2017, LifeVantage Corporation (the “Company”) issued a press release announcing its financial results for the fiscal year ended June 30, 2017. A copy of the Company’s press release is attached as Exhibit 99.1 to this report and incorporated by reference.
The information furnished in this Item 2.02 and the exhibit hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01.    Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No.
 
Description

99.1
 
 


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
 
Date:
September 7, 2017
LIFEVANTAGE CORPORATION

By: /s/ Steven R. Fife
Name: Steven R. Fife
Title: Chief Financial Officer



Exhibit
https://cdn.kscope.io/d63e5743d40b5f107261d377b5c11bd7-logoa07.jpg

LifeVantage Announces Financial Results for the
Fourth Fiscal Quarter and Full Fiscal Year 2017
Reports 12.5% sequential fourth quarter revenue growth
Increases global footprint with expansion into Germany
Salt Lake City, UT, September 7, 2017, LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its fourth quarter and full year ended June 30, 2017.
“We finished fiscal 2017 on a strong note, posting 12.5% sequential revenue growth compared to the third quarter,” stated LifeVantage President and Chief Executive Officer Darren Jensen. “I am excited about the progress we have and are making against each of our key focus areas. We are in a transformational period where we are building the assets to transform our business model into a technology powered solution for both distributors and consumers with enhanced tools, product solutions and business development activities. As fiscal 2018 progresses, we will be rolling out a series of initiatives that support each of our key focus areas, investing in technologies that set us apart from our peers and investing in our distribution network. We are laying the groundwork for both near-term growth and long-term success in a new economy with consumers that are more engaged and empowered than ever to leverage the LifeVantage offerings.”
Fourth Quarter Fiscal 2017 Highlights:
Revenue increased 12.5% sequentially to $50.6 million when compared to $45.0 million in the third quarter of fiscal 2017 and decreased 4.5% when compared to $53.0 million in the fourth quarter of fiscal 2016;
Revenue in the Americas increased 12.6% and revenue in Asia/Pacific & Europe increased 12.2%, both when compared sequentially to the third quarter of fiscal 2017. On a year over year basis, revenue in the Americas decreased 2.0% and revenue in Asia/Pacific & Europe decreased 11.9%. However, revenue in Japan increased 6.7% year over year;
Active independent distributors and active preferred customers increased 1.6% and 0.9%, respectively, when compared to the third quarter of fiscal 2017;
Adjusted EBITDA increased 100.6% to $3.3 million when compared to $1.6 million in the third quarter of fiscal 2017 and decreased 41.7% when compared to $5.6 million in the comparable period of fiscal 2016;
Earnings per diluted share were $0.01, compared to $0.00 in the third quarter of fiscal 2017 and $0.17 in the fourth quarter of fiscal 2016;
Adjusted earnings per diluted share were $0.04, compared to $0.02 in the third quarter of fiscal 2017 and $0.23 in the fourth quarter of fiscal 2016; and
On September 1, 2017, the Company officially opened for business in Germany, the fourth largest direct selling market globally.
Fiscal Year 2017 Highlights:
Revenue decreased 3.4% to $199.5 million, compared to $206.5 million in fiscal 2016;
Revenue in the Americas decreased 4.7% and revenue in Asia/Pacific & Europe increased 0.8%, both when compared to fiscal 2016;
Adjusted EBITDA decreased 33.4% to $13.1 million, compared to $19.7 million for fiscal 2016;
Earnings per diluted share were $0.11, compared to $0.42 in fiscal 2016; and
Adjusted earnings per diluted share were $0.27, compared to $0.64 in fiscal 2016.



https://cdn.kscope.io/d63e5743d40b5f107261d377b5c11bd7-logoa07.jpg

Fourth Quarter Fiscal 2017 Results
For the fourth fiscal quarter ended June 30, 2017, the Company reported revenue of $50.6 million a decrease of 4.5% as compared to $53.0 million in the comparable period in fiscal 2016. Revenue in the Americas for the fourth quarter decreased 2.0% compared to the fourth quarter of fiscal 2016. Revenue in the Asia/Pacific & Europe region decreased 11.9% compared to the fourth quarter of fiscal 2016. However, revenue in Japan increased by 6.7% compared to the fourth quarter of fiscal 2016. Revenue for the fourth fiscal quarter ended June 30, 2017, was negatively impacted $0.4 million, or 0.7%, by foreign currency fluctuations associated with revenue generated in several international markets when compared to the fourth quarter of fiscal 2016.
Gross profit for the fourth quarter of fiscal 2017 was $41.8 million, or 82.4% of revenue, compared to $43.6 million, or 82.3% of revenue, for the same period in fiscal 2016. Commissions and incentives expense for the fourth quarter of fiscal 2017 was $24.0 million, or 47.4% of revenue, compared to $25.6 million, or 48.3% of revenue, for the same period in fiscal 2016. Selling, general and administrative expense (SG&A) for the fourth quarter of fiscal 2017 was $16.2 million, or 32.0% of revenue, compared to $14.0 million, or 26.3% of revenue, in the comparable period of fiscal 2016.
Operating income for the fourth quarter of fiscal 2017 was $1.5 million, compared to $4.1 million for the fourth quarter of fiscal 2016. Operating income during the fourth quarter of fiscal 2017 included approximately $0.2 million for expenses associated with executive team recruiting and transition expenses, $0.1 million of class-action lawsuit expense and $0.2 million of other nonrecurring legal expenses. Adjusted EBITDA was $3.3 million for the fourth quarter of fiscal 2017, compared to $5.6 million for the comparable period in fiscal 2016.
Net income for the fourth quarter of fiscal 2017 was $0.1 million, or $0.01 per diluted share. This compares to net income for the fourth quarter of fiscal 2016 of $2.4 million, or $0.17 per diluted share. Adjusted for net recruiting and transition expenses of $0.2 million, class-action lawsuit expense of $0.1 million, other nonrecurring legal expenses of $0.2 million, and a write off of intangible assets of $0.4 million, net of $0.4 million of tax impacts of these adjustments, adjusted Non-GAAP net income was $0.5 million for the fourth quarter of fiscal 2017, or $0.04 per diluted share; compared to $3.3 million, or $0.23 per diluted share for the comparable period of fiscal 2016. Non-GAAP adjustments to net income during the fourth quarter of fiscal 2016 included a write-off of capitalized software development costs of $1.2 million, net of $0.4 million of tax impacts.
Fiscal 2017 Full Year Results
For the fiscal year ended June 30, 2017, the Company reported net revenue of $199.5 million, a decrease of 3.4% compared to $206.5 million for fiscal 2016. In fiscal 2017, revenue in the Americas decreased 4.7%, while revenue in Asia/Pacific & Europe increased 0.8%. Revenue for fiscal 2017 was positively impacted $2.4 million, or 1.2%, by foreign currency fluctuations which is related primarily to our Asia/Pacific & Europe region.
Gross profit for fiscal 2017 was $166.0 million, or 83.2% of revenue, compared to $172.6 million, or 83.6% of revenue, for fiscal 2016. Commissions and incentives expense for fiscal 2017 was $96.7 million, or 48.5% of revenue, compared to $103.1 million, or 49.9% of revenue, for fiscal 2016. SG&A for fiscal 2017 was $64.9 million, or 32.5% of revenue, compared to $56.1 million, or 27.1% of revenue, for fiscal 2016.
Operating income for fiscal 2017 was $4.4 million, compared to $13.4 million for fiscal 2016. Operating income for the fiscal year ended June 30, 2017 includes $2.7 million for expenses associated with the Audit Committee independent review, $0.8 million for executive severance, recruiting and transition expenses, $0.2 million of class-action lawsuit expense and $0.2 million of other nonrecurring legal expenses. Operating income for fiscal 2016 includes $1.7 million of executive transition expenses and costs associated with the reverse stock split during fiscal 2016. Adjusted EBITDA was $13.1 million for fiscal 2017, compared to $19.7 million for fiscal 2016.
Net income for fiscal 2017 was $1.6 million, or $0.11 per diluted share, compared to $6.1 million, or $0.42 per diluted share for fiscal 2016. Adjusting for previously announced expenses associated with the audit committee independent review of $2.7 million, $0.8 million of costs for net executive severance, recruiting and transition expenses, $0.2 million of class-action lawsuit expense, $0.2 million of other nonrecurring legal expenses and a write-off of intangible assets of $0.4 million, net of $1.9 million of tax impacts of these adjustments, adjusted Non-GAAP net income for the fiscal year ended June 30, 2017 was $3.9 million, or $0.27 per diluted share. Adjusting for executive transition and severance


https://cdn.kscope.io/d63e5743d40b5f107261d377b5c11bd7-logoa07.jpg

expenses and costs associated with the reverse stock split of $1.7 million, collectively, along with a $1.2 million write-off of capitalized software development costs and a $1.5 million write-off of deferred debt transaction costs, net of $1.3 million of tax impacts of these adjustments, adjusted Non-GAAP net income for fiscal 2016 was $9.2 million or $0.64 per diluted share.
Balance Sheet & Liquidity
The Company generated $6.6 million of cash from operations during fiscal 2017 compared to $6.0 million in fiscal 2016. The year-over-year increase in cash provided by operations during fiscal 2017 relates to working capital improvements made during this year, primarily a reduction of inventory and prepaid deposits partially offset by decreases in accounts payable and income tax liabilities. The Company's cash and cash equivalents at June 30, 2017 were $11.5 million, an increase of $3.6 million when compared to $7.9 million at June 30, 2016. Total debt at June 30, 2017 was $7.4 million compared to $9.4 million at June 30, 2016.
Fiscal Year 2018 Guidance
The Company expects to generate revenue in the range of $206 million to $212 million in fiscal year 2018 and anticipates diluted earnings per share in the range of $0.40 to $0.50.
Revised Results
The financial information included herein has been revised to correct immaterial errors present in prior periods. See the Company's Form 10-K for a summary of the revisions.
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MDT (4:30 p.m. EDT). Investors interested in participating in the live call can dial (800) 279-9534 from the U.S. International callers can dial (719) 457-2080. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, September 14, 2017, by dialing (844) 512-2921 from the U.S. and entering confirmation code 2297405, or (412) 317-6671 from international locations, and entering confirmation code 2297405.
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at http://investor.lifevantage.com/events.cfm. The webcast will be archived for approximately 30 days.
About LifeVantage Corporation
LifeVantage Corporation is a science-based health, wellness and anti-aging company dedicated to helping people transform themselves internally and externally at a cellular level. Their scientifically-validated product lines include Protandim® Nrf2 and NRF1 Synergizers, TrueScience® Anti-Aging Skin Care Regimen, Petandim® for Dogs, AXIO® Smart Energy and the PhysIQ™ Smart Weight Management System. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah. For more information, visit www.lifevantage.com.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to" and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding our future operating results, implementation of our strategic initiatives, , distributor success and shareholder value. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information


https://cdn.kscope.io/d63e5743d40b5f107261d377b5c11bd7-logoa07.jpg

currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income and Non-GAAP Earnings per Share as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.

Investor Relations Contacts:
Cindy England
Director of Investor Relations
(801) 432-9036
cengland@lifevantage.com

-or-

Scott Van Winkle
Managing Director, ICR
(617) 956-6736
scott.vanwinkle@icrinc.com


https://cdn.kscope.io/d63e5743d40b5f107261d377b5c11bd7-logoa07.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(unaudited)
 
As of
 
June 30, 2017
 
June 30, 2016
(In thousands, except per share data)
 
 
(As Revised)
ASSETS
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
11,458

 
$
7,883

Accounts receivable
1,334

 
1,552

Income tax receivable
913

 

Inventory, net
16,575

 
25,116

Current deferred income tax asset

 
2,260

Prepaid expenses and deposits
5,266

 
6,301

     Total current assets
35,546

 
43,112

 
 
 
 
Property and equipment, net
3,127

 
3,456

Intangible assets, net
1,247

 
1,744

Long-term deferred income tax asset
4,087

 
1,023

Other long-term assets
1,242

 
1,520

TOTAL ASSETS
$
45,249

 
$
50,855

 
 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities
 
 
 
Accounts payable
$
4,850

 
$
8,891

Commissions payable
6,837

 
7,719

Income tax payable
215

 
3,284

Other accrued expenses
9,453

 
8,734

Current portion of long-term debt
2,000

 
2,000

Total current liabilities
23,355

 
30,628

 
 
 
 
Long-term debt
 
 
 
Principal amount
5,500

 
7,500

Less: unamortized discount and deferred offering costs
(60
)
 
(91
)
Long-term debt, net of unamortized discount and deferred offering costs
5,440

 
7,409

Other long-term liabilities
1,927

 
2,169

     Total liabilities
30,722

 
40,206

Commitments and contingencies
 
 
 
Stockholders' equity
 
 
 
Preferred stock — par value $0.001, 50,000 shares authorized, no shares issued or outstanding

 

Common stock — par value $0.001, 250,000 shares authorized and 14,232 and 14,028 issued and outstanding as of June 30, 2017 and 2016, respectively
14

 
14

Additional paid-in capital
121,599

 
119,242

Accumulated deficit
(106,992
)
 
(108,600
)
Accumulated other comprehensive income (loss)
(94
)
 
(7
)
     Total stockholders’ equity
14,527

 
10,649

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
$
45,249

 
$
50,855



https://cdn.kscope.io/d63e5743d40b5f107261d377b5c11bd7-logoa07.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
 
 
 
 
 
 
 
 
 
For the Three Months Ended June 30,
(Unaudited)
 
For the Twelve Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
(In thousands, except per share data)
 
 
(As revised)
 
 
 
(As revised)
Revenue, net
$
50,641

 
$
53,033

 
$
199,489

 
$
206,540

Cost of sales
8,891

 
9,401

 
33,456

 
33,932

Gross profit
41,750

 
43,632

 
166,033

 
172,608

Operating expenses:
 
 
 
 
 
 
 
Commissions and incentives
23,984

 
25,595

 
96,662

 
103,120

Selling, general and administrative
16,226

 
13,957

 
64,922

 
56,074

Total operating expenses
40,210

 
39,552

 
161,584

 
159,194

Operating income
1,540

 
4,080

 
4,449

 
13,414

Other expense:
 
 
 
 
 
 
 
Interest expense
(164
)
 
(145
)
 
(570
)
 
(3,321
)
Other expense, net
(616
)
 
(1,153
)
 
(969
)
 
(1,409
)
Total other expense
(780
)
 
(1,298
)
 
(1,539
)
 
(4,730
)
Income before income taxes
760

 
2,782

 
2,910

 
8,684

Income tax expense
(676
)
 
(345
)
 
(1,302
)
 
(2,578
)
Net income
$
84

 
$
2,437

 
$
1,608

 
$
6,106

Net income per share:
 
 
 
 
 
 
 
Basic
$
0.01

 
$
0.18

 
$
0.12

 
$
0.44

Diluted
$
0.01

 
$
0.17

 
$
0.11

 
$
0.42

Weighted-average shares outstanding:
 
 
 
 
 
 
 
Basic
13,952

 
13,758

 
13,881

 
13,730

Diluted
14,085

 
14,640

 
14,118

 
14,531

 
 
 
 
 
 
 
 
Other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
Foreign currency translation adjustment
(15
)
 
116

 
(87
)
 
244

Other comprehensive income (loss), net of tax:
(15
)
 
116

 
(87
)
 
244

Comprehensive income
$
69

 
$
2,553

 
$
1,521

 
$
6,350




https://cdn.kscope.io/d63e5743d40b5f107261d377b5c11bd7-logoa07.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Revenue by Region
 
 
For the Three Months Ended
June 30,
(unaudited)
 
For the Twelve Months Ended
June 30,
 
2017
 
2016
 
2017
 
2016
(In thousands)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Americas
$
38,714

 
76
%
 
$
39,498

 
74
%
 
$
150,841

 
76
%
 
$
158,291

 
77
%
Asia/Pacific & Europe
11,927

 
24
%
 
13,535

 
26
%
 
48,648

 
24
%
 
48,249

 
23
%
Total
$
50,641

 
100
%
 
$
53,033

 
100
%
 
$
199,489

 
100
%
 
$
206,540

 
100
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Active Independent Distributors (1)
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
June 30,
 
 
 
 
 
 
 
 
 
2017
 
2016
 
 
 
 
 
 
 
 
Americas
47,000

 
73
%
 
49,000

 
71
%
 
 
 
 
 
 
 
 
Asia/Pacific & Europe
17,000

 
27
%
 
20,000

 
29
%
 
 
 
 
 
 
 
 
Total
64,000

 
100
%
 
69,000

 
100
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Active Preferred Customers (2)
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
June 30,
 
 
 
 
 
 
 
 
 
2017
 
2016
 
 
 
 
 
 
 
 
Americas
90,000

 
80
%
 
95,000

 
81
%
 
 
 
 
 
 
 
 
Asia/Pacific & Europe
22,000

 
20
%
 
22,000

 
19
%
 
 
 
 
 
 
 
 
Total
112,000

 
100
%
 
117,000

 
100
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Active Independent Distributors have purchased product in the prior three months for retail or personal consumption.
(2) Active Preferred Customers have purchased product in the prior three months for personal consumption only.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



https://cdn.kscope.io/d63e5743d40b5f107261d377b5c11bd7-logoa07.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA:
(Unaudited)
 
 
 
 
 
For the Three Months Ended June 30,
 
For the Twelve Months Ended June 30,
 
2017
 
2016
 
2017
 
2016
(In thousands)
 
 
(As Revised)
 
 
 
(As Revised)
GAAP Net income
$
84

 
$
2,437

 
$
1,608

 
$
6,106

Interest expense
164

 
145

 
570

 
3,321

Provision for income taxes
676

 
345

 
1,302

 
2,578

Depreciation and amortization
418

 
471

 
1,643

 
1,895

Non-GAAP EBITDA:
1,342

 
3,398

 
5,123

 
13,900

Adjustments:
 
 
 
 
 
 
 
Stock compensation expense
855

 
1,045

 
2,647

 
2,621

Other income, net
616

 
1,153

 
969

 
1,409

Other adjustments(1)
446

 
(7
)
 
4,348

 
1,720

Total adjustments
1,917

 
2,191

 
7,964

 
5,750

Non-GAAP Adjusted EBITDA
$
3,259

 
$
5,589

 
$
13,087

 
$
19,650

 
 
 
 
 
 
 
 
(1) Other adjustments for the three months ended June 30, 2017 include approximately $0.2 million for executive search firm expenses, $0.2 million for other nonrecurring legal expenses and $0.1 for expenses associated with ongoing class-action lawsuits. Other adjustments for the three months ended June 30, 2016 include approximately ($7,000) for net severance, search firm and hiring expenses. Other adjustments for the twelve months ended June 30, 2017 include approximately $2.7 million for expenses associated with the audit committee independent review, $1.3 million for executive severance and search firm expenses, $0.2 million for other nonrecurring legal expenses and $0.2 million associated with the ongoing class-action lawsuits. Other adjustments for the twelve months ended June 30, 2016 include approximately $0.7 million for executive severance expenses, $0.9 million for search firm and hiring expenses associated with the search for executive officers, and $0.1 million for expenses associated with the reverse stock split completed during October 2015.



https://cdn.kscope.io/d63e5743d40b5f107261d377b5c11bd7-logoa07.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS:
(Unaudited)
 
 
 
 
 
For the Three Months Ended June 30,
 
For the Twelve Months Ended June 30,
 
2017
 
2016
 
2017
 
2016(1)
(In thousands)
 
 
(As Revised)
 
 
 
(As Revised)
GAAP Net income
$
84

 
$
2,437

 
$
1,608

 
$
6,106

Adjustments:
 
 
 
 
 
 
 
Executive team severance expenses, net (2)

 
(45
)
 
39

 
632

Executive team recruiting and transition expenses
203

 
38

 
744

 
928

Reverse stock split administrative expenses

 

 

 
159

Write-off of deferred debt transaction costs

 

 

 
1,544

Write-off of capitalized software development costs

 
1,186

 

 
1,186

Audit committee independent review expenses

 

 
2,742

 

Class-action lawsuit expenses
84

 

 
170

 

Other nonrecurring legal expenses
160

 

 
160

 

Write-off of intangible assets
350

 

 
350

 

Tax impact of adjustments
(356
)
 
(350
)
 
(1,881
)
 
(1,320
)
Total adjustments, net of tax
441

 
829

 
2,324

 
3,129

Non-GAAP Net Income:
$
525

 
$
3,266

 
$
3,932

 
$
9,235

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the Three Months Ended June 30,
 
For the Twelve Months Ended June 30,
 
2017
 
2016
 
2017
 
2016(1)
 
 
 
(As Revised)
 
 
 
(As Revised)
Diluted earnings per share, as reported
$
0.01

 
$
0.17

 
$
0.11

 
$
0.42

Total adjustments, net of tax
0.03

 
0.06

 
0.16

 
0.22

Diluted earnings per share, as adjusted
$
0.04

 
$
0.23

 
$
0.27

 
$
0.64

 
 
 
 
 
 
 
 
(1) Executive team severance expenses for the prior period non-GAAP adjustments have been restated from previously reported results to display these expenses net of unvested stock award reversals for comparability purposes.
 
 
 
 
 
 
 
 
(2) Net of $493,000 of compensation expense benefit related to unvested stock award reversals for the twelve months ended June 30, 2017. Net of $191,000 of compensation expense benefit related to unvested stock award reversals for the twelve months ended June 30, 2016.